Patents by Inventor Fahad Al-Obeidi
Fahad Al-Obeidi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9957294Abstract: A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also provided are antibodies that specifically bind to a peptide comprising a phosphohistidine (or a non-hydrolyzable pHis analogue) but fail to specifically bind to an identical peptide containing histidine instead of phosphohistidine.Type: GrantFiled: September 12, 2014Date of Patent: May 1, 2018Assignees: Salk Institute for Biological Studies, SanofiInventors: Magda Stankova, Fahad Al-Obeidi, Jacques Mauger, Robert A. Binnie, Tony Hunter, Jill Meisenhelder, Stephen Rush Fuhs
-
Patent number: 9850319Abstract: Isolated monoclonal antibodies and or antigen binding fragments thereof are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at N3 (3-pHis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed. Methods are also disclosed for using these antibodies, such as for detection of polypeptides comprising a histidine phosphorylated at N3 (3-pHis). In some embodiments, the methods can be used to investigate signal transduction pathways.Type: GrantFiled: July 1, 2015Date of Patent: December 26, 2017Assignees: Salk Institute for Biological Studies, SanofiInventors: Tony Hunter, Stephen Rush Fuhs, Jill Meisenhelder, Jacques Mauger, Magda Stankova, Fahad Al-Obeidi, Robert A. Binne
-
Publication number: 20170210824Abstract: Isolated monoclonal antibodies and or antigen binding fragments thereof are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at N3 (3-pHis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed. Methods are also disclosed for using these antibodies, such as for detection of polypeptides comprising a histidine phosphorylated at N3 (3-pHis). In some embodiments, the methods can be used to investigate signal transduction pathways.Type: ApplicationFiled: July 1, 2015Publication date: July 27, 2017Applicants: Salk Institute for Biological Studies, SanofiInventors: Tony Hunter, Stephen Rush Fuhs, Jill Meisenhelder, Jacques Mauger, Fahad Al-Obeidi, Robert A. Binne
-
Publication number: 20150065395Abstract: A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also provided are antibodies that specifically bind to a peptide comprising a phosphohistidine (or a non-hydrolyzable pHis analogue) but fail to specifically bind to an identical peptide containing histidine instead of phosphohistidine.Type: ApplicationFiled: March 13, 2013Publication date: March 5, 2015Inventors: Magda Stankova, Fahad Al-Obeidi, Jacques Mauger, Robert A. Binnie, Tony Hunter, Jill Meisenhelder, Stephen Rush Fuhs
-
Publication number: 20150004173Abstract: A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also provided are antibodies that specifically bind to a peptide comprising a phosphohistidine (or a non-hydrolyzable pHis analogue) but fail to specifically bind to an identical peptide containing histidine instead of phosphohistidine.Type: ApplicationFiled: September 12, 2014Publication date: January 1, 2015Inventors: Magda Stankova, Fahad Al-Obeidi, Jacques Mauger, Robert A. Binnie, Tony Hunter, Jill Meisenhelder, Stephen Rush Fuhs
-
Patent number: 7825115Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.Type: GrantFiled: January 10, 2008Date of Patent: November 2, 2010Assignee: Aventis Pharma S.A.Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
-
Patent number: 7435747Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: July 7, 2004Date of Patent: October 14, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventors: Anuschirwan Peyman, David William Will, Uwe Gerlach, Marc Nazaré, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Publication number: 20080108654Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.Type: ApplicationFiled: January 10, 2008Publication date: May 8, 2008Applicant: AVENTIS PHARMA S.A.Inventors: Marcel PATEK, Anil NAIR, Augustin HITTINGER, Conception NEMECEK, Daniel BOND, Greg HARLOW, Herve BOUCHARD, Jacques MAUGER, Jean-Luc MALLERON, Mark PALERMO, Fahad AL-OBEIDI, Thomas FAITG, Hartmut STROBEL, Sven RUF, Kurt RITTER, Youssef EL-AHMAD, Dominique LESUISSE
-
Patent number: 7354933Abstract: The present invention relates to a cyclic urea compound of formula I: as defined herein. The invention is also directed to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use, as an inhibitor on a protein kinase. Thus, it is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.Type: GrantFiled: February 2, 2004Date of Patent: April 8, 2008Assignee: Aventis Pharma SAInventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
-
Publication number: 20050143419Abstract: The present invention relates to compounds of the formula I, in which R0; Q; X; Q?, D, R10 and V have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: July 7, 2004Publication date: June 30, 2005Applicant: Aventis Pharma Deutschland GmbHInventors: Anuschirwan Peyman, David Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Publication number: 20040248884Abstract: The present invention relates to a cyclic urea compound of formula I: 1Type: ApplicationFiled: February 2, 2004Publication date: December 9, 2004Applicant: AVENTIS PHARMA S.A.Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse
-
Patent number: 6794365Abstract: The present invention relates to new malonic acid derivatives of the formula I, wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicated in the claims. The compounds of formula I are inhibitors of the blood clotting enzyme factor Xa. The invention also relates to processes for the preparation of the compounds of formula I, to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula I in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and to the use of the compounds of formula I in the preparation of medicaments to be applied in such diseases.Type: GrantFiled: February 23, 2001Date of Patent: September 21, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Fahad A. Al-Obeidi, Armin Walser, Peter Wildgoose
-
Patent number: 6759384Abstract: The invention provides compounds which specifically inhibit factor Xa activity having the structure A1—A2—(A3)m—B, where m is 0 or 1. A compound of the invention is characterized, in part, in that it exhibits a specific inhibition of factor Xa activity with a Ki≦100 &mgr;M, preferably ≦2 nM, and does not substantially inhibit the activity of other proteases involved in the coagulation cascade. The invention further provides methods of specifically inhibiting the activity of factor Xa and of inhibiting blood clotting in vitro and in an individual and methods of detecting factor Xa levels or activity.Type: GrantFiled: December 14, 1998Date of Patent: July 6, 2004Assignee: Aventis Pharmaceuticals Inc.Inventors: Fahad Al-Obeidi, Michal Lebl, James A. Ostrem, Pavel Safar, Alena Stierandova, Peter Strop, Armin Walser
-
Patent number: 6759420Abstract: The present invention is directed to new compounds for the inhibition of blood clotting proteins and factor Xa activity, and more particularly, to arylalkanoyl derivatives of the formula (I): wherein R(1), R(2), R(3), R(4), R(5), R(6a), and R(6b) have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (I), to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula (I) in the treatment and prophylaxis of diseases whcih can be treated or prevented by the inhibition of factor Xa activity, such as cardiovascular or thromboembolic diseases, and to the use of the compounds of formula (I) in the preparation of medicaments to be applied in such diseases.Type: GrantFiled: December 28, 1999Date of Patent: July 6, 2004Assignee: Aventis Pharma Deutschland GmbHInventors: Elisabeth Defossa, Uwe Heinelt, Otmar Klingler, Gerhard Zoller, Hans Matter, Fahad A. Al-Obeidi, Armin Walser, Peter Wildgoose
-
Publication number: 20040014676Abstract: Amide containing aromatic compounds having an inhibitory effect on Src kinase including enantiomers, stereoisomers and tautomers thereof, as well as pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formulae I through XVIII.Type: ApplicationFiled: July 9, 2002Publication date: January 22, 2004Inventors: Ramalinga Dharanipragada, Fahad Al-Obeidi, Gary Flynn, Dasha Cabel
-
Patent number: 6664393Abstract: The present invention relates to compounds of the formula I, in which A, L, Y, and k have the meanings indicated in the specification and claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa and/or factor VIIa and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of conditions in which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: August 26, 2002Date of Patent: December 16, 2003Assignee: Aventis Pharma Deutschland GmbHInventors: Otmar Klingler, Gerhard Zoller, Elisabeth Defossa, Fahad A. Al-Obeidi, Armin Walser, James Ostrem
-
Publication number: 20030162967Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: August 26, 2002Publication date: August 28, 2003Applicant: Aventis Pharma Deutschland GmbHInventors: Otmar Klingler, Gerhard Zoller, Elisabeth Defossa, Fahad A. Al-Obeidi, Armin Walser, James Ostrem
-
Publication number: 20020173656Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: December 6, 2001Publication date: November 21, 2002Inventors: Anuschirwan Peyman, David William Will, Uwe Gerlach, Marc Nazare, Gerhard Zoller, Hans-Peter Nestler, Hans Matter, Fahad Al-Obeidi
-
Patent number: 6472562Abstract: The present invention relates to compounds of the formula I, in which A, L, Y, and k have the meanings indicated in the specification and claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa and/or factor VIIa and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of conditions in which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: October 27, 2000Date of Patent: October 29, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Otmar Klingler, Gerhard Zoller, Elisabeth Defossa, Fahad A. Al-Obeidi, Armin Walser, James Ostrem
-
Patent number: 6395737Abstract: New compounds for the inhibition of blood clotting proteins, and more particularly, to malonic acid derivatives of the formula I, wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicated in the claims. The compounds of formula I are inhibitors of the blood clotting enzyme factor Xa. Processes for the preparation of the compounds of formula I, methods of inhibiting factor Xa activity and of inhibiting blood clotting, use of the compounds of formula I in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and use of the compounds of formula I in the preparation of medicaments to be applied in such diseases. Compositions containing a compound of formula I in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula I together with pharmaceutically acceptable carrier substances and auxiliary substances.Type: GrantFiled: December 28, 1999Date of Patent: May 28, 2002Assignee: Aventis Pharma Deutschland GmbHInventors: Elisabeth Defossa, Uwe Heinelt, Otmar Klingler, Gerhard Zoller, Hans Matter, Fahad A. Al-Obeidi, Armin Walser, Peter Wildgoose